Rosetta Genomics Ltd. (USA)  

(Public, NASDAQ:ROSG)   Watch this stock  
Find more results for heart disease
1.25
-0.06 (-4.58%)
May 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.25 - 1.34
52 week 0.71 - 4.13
Open 1.32
Vol / Avg. 30,211.00/188,455.00
Mkt cap 25.67M
P/E     -
Div/yield     -
EPS -1.12
Shares 20.85M
Beta -3.36
Inst. own 12%
Mar 23, 2016
Q4 2015 Rosetta Genomics Ltd Earnings Call
Mar 23, 2016
Full Year 2015 Rosetta Genomics Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -188.90% -209.78%
Operating margin -143.86% -190.14%
EBITD margin - -182.97%
Return on average assets -127.70% -87.38%
Return on average equity -146.57% -100.01%
Employees 77 -
CDP Score - -

Address

10 Plaut Street, Science Park, POB 4059
REHOVOT, 7670609
Israel
+972-7-32220700 (Phone)
+972-7-32220701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rosetta Genomics Ltd. is a molecular diagnostics company advancing microRNA-based diagnostics discovered and developed through its microRNAs and platform technologies. The Company has developed platform technologies for the identification, extraction, quantification and analysis of microRNAs from a range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects in cancer, cardiovascular diseases and other indications. The Company's four commercial oncology tests have been launched in multiple countries across the world. The Company is working to develop additional tests in the cancer realm and in other fields. It is marketing and selling the four diagnostic tests based on its microRNA technologies, which include Rosetta Cancer Origin Test, Rosetta Lung Cancer Test, Rosetta Kidney Cancer Test and Rosetta Mesothelioma Test. The Company's therapeutic pipeline consists of the projects, such as CMV Therapeutic and Rimonim Consortium.

Officers and directors

Brian A. Markison Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Kenneth A. Berlin President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Ron Kalfus Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
Douglas Sites Executive Vice President - Sales and Marketing
Bio & Compensation  - Reuters
Dganit Bar Ph.D. Chief Scientific Officer
Age: 46
Bio & Compensation  - Reuters
Eti Meiri Ph.D. Vice President - Research
Age: 46
Bio & Compensation  - Reuters
Oded Biran General Counsel
Age: 36
Bio & Compensation  - Reuters
E. Robert Wassman M.D. Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Kevin Watson Director, Reimbursement-Managed Care
Bio & Compensation  - Reuters
Roy N. Davis Director
Age: 68
Bio & Compensation  - Reuters